|
|
|
|
MT Nakada, JM Stadel, KS Poksay and ST Crooke
Treatment of 3T3-L1 preadipocytes (fibroblasts) with 250 nM dexamethasone for 48 hr caused a doubling of total beta-adrenergic receptors and an increase in beta 2-adrenergic receptor subtype proportion from approximately 50% in controls to 85% in treated cells. The responses to epinephrine and norepinephrine in a whole cell cAMP accumulation assay reflected these changes. The effects of dexamethasone on beta-adrenergic receptors were mediated through the glucocorticoid receptor and were time and dose dependent with an EC50 of 2.77 +/- 0.73 nM for an increase in the proportion of beta 2- adrenergic receptors. The rank order of potency of steroids to effect these changes (betamethasone = dexamethasone greater than fludrocortisone greater than hydrocortisone = triamcinolone greater than aldosterone) correlated with their glucocorticoid potency. [3H]Dexamethasone binding to intact cells yielded a KD value of 3.47 +/- 0.38 nM for binding to the glucocorticoid receptor which correlated well with the EC50 for dexamethasone to alter beta-adrenergic receptors. Inhibition of [3H]dexamethasone binding by other steroids confirmed that the ability of steroids to regulate beta-adrenergic receptors correlated with the affinity of each compound for the 3T3-L1 glucocorticoid receptor. Progesterone, which can bind to the glucocorticoid receptor but has only weak agonist activity, competitively inhibited the ability of dexamethasone to alter beta- adrenergic receptors. Protein synthesis, RNA synthesis, and N-linked glycosylation appeared to be necessary for the change in receptor subtype expression and the increase in beta-adrenergic receptor number induced by dexamethasone. The present study suggests that regulation of beta-adrenergic receptor expression in 3T3-L1 preadipocytes by dexamethasone is a glucocorticoid-specific effect which may require gene activation.
This article has been cited by other articles:
![]() |
D. P Macfarlane, S. Forbes, and B. R Walker Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome J. Endocrinol., May 1, 2008; 197(2): 189 - 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
R H Straub, R Wiest, U G Strauch, P Harle, and J Scholmerich The role of the sympathetic nervous system in intestinal inflammation. Gut, November 1, 2006; 55(11): 1640 - 1649. [Full Text] [PDF] |
||||
![]() |
P Harle, R H Straub, R Wiest, A Mayer, J Scholmerich, F Atzeni, M Carrabba, M Cutolo, and P Sarzi-Puttini Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems Ann Rheum Dis, January 1, 2006; 65(1): 51 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
R H Straub, F Buttgereit, and M Cutolo Benefit of pregnancy in inflammatory arthritis Ann Rheum Dis, June 1, 2005; 64(6): 801 - 803. [Full Text] [PDF] |
||||
![]() |
J. A. Villena, S. Roy, E. Sarkadi-Nagy, K.-H. Kim, and H. S. Sul Desnutrin, an Adipocyte Gene Encoding a Novel Patatin Domain-containing Protein, Is Induced by Fasting and Glucocorticoids: ECTOPIC EXPRESSION OF DESNUTRIN INCREASES TRIGLYCERIDE HYDROLYSIS J. Biol. Chem., November 5, 2004; 279(45): 47066 - 47075. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. STRAUB, C. GUNZLER, L. E. MILLER, M. CUTOLO, J. SCHOLMERICH, and S. SCHILL Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro FASEB J, July 1, 2002; 16(9): 993 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Fève, F. Piétri-Rouxel, K. E. Hadri, M.-F. Drumare, and A. D. Strosberg Long Term Phorbol Ester Treatment Down-regulates the [IMAGE][IMAGE]-Adrenergic Receptor in 3T3-F442A Adipocytes J. Biol. Chem., May 5, 1995; 270(18): 10952 - 10959. [Abstract] [Full Text] [PDF] |
||||